Enterprise Value

4.706M

Cash

80.02M

Avg Qtr Burn

-22.14M

Short % of Float

6.57%

Insider Ownership

11.43%

Institutional Own.

61.09%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Zokinvy™ (lonafarnib) Details
HGPS (Hutchinson-Gilford Progeria Syndrome) or Progeria

Approved

Quarterly sales

BLA

Submission

Peginterferon Lambda (Lambda) Details
Infectious disease, Hepatitis D

Phase 3

Data readout

Lonafarnib (Ritonavir) Details
Infectious disease, Liver disease, Hepatitis D

Phase 3

Data readout

Avexitide/GLP-1 Antagonist Details
Congenital Hyperinsulinism, Metabolic disorder

Phase 3

Update

Peginterferon Lambda + Lonafarnib Details
Hepatitis D, Infectious disease

Phase 2

Initiation